- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- September 2024
- 82 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- October 2023
- 173 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- May 2023
- 160 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- October 2023
- 145 Pages
Global
From €3006EUR$3,150USD£2,519GBP
- Report
- June 2022
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- January 2022
- 112 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2019
- 128 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- January 2024
- 243 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- April 2018
United States
From €7630EUR$7,995USD£6,393GBP
- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- September 2022
- 242 Pages
Global
From €3407EUR$3,570USD£2,855GBP
Interleukin inhibitors are a type of immune disorder drug used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the action of interleukins, which are proteins that play a role in inflammation and the body's immune response. Interleukin inhibitors can be used alone or in combination with other drugs to reduce inflammation and improve symptoms.
The interleukin inhibitor market is a rapidly growing segment of the immune disorder drug market. It is expected to continue to grow as more treatments become available and as the demand for treatments for immune-related conditions increases.
Some of the major companies in the interleukin inhibitor market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, and Pfizer. These companies are actively researching and developing new treatments for immune-related conditions. Show Less Read more